(secondQuint)Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD.

 Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of RXI-109 when administered by intravitreal injection.

 Evaluate the clinical activity of single and multiple doses of RXI-109 when administered by intravitreal injection.

 Study participation is intended to be seven months from time of initial treatment with RXI-109.

.

 Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD@highlight

This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular age-related macular degeneration (NVAMD).

